Cargando…

Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis

PURPOSE: Periodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-...

Descripción completa

Detalles Bibliográficos
Autores principales: Steckiewicz, Karol P, Cieciórski, Piotr, Barcińska, Ewelina, Jaśkiewicz, Maciej, Narajczyk, Magdalena, Bauer, Marta, Kamysz, Wojciech, Megiel, Elżbieta, Inkielewicz-Stepniak, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820264/
https://www.ncbi.nlm.nih.gov/pubmed/35140461
http://dx.doi.org/10.2147/IJN.S339046
_version_ 1784646192823533568
author Steckiewicz, Karol P
Cieciórski, Piotr
Barcińska, Ewelina
Jaśkiewicz, Maciej
Narajczyk, Magdalena
Bauer, Marta
Kamysz, Wojciech
Megiel, Elżbieta
Inkielewicz-Stepniak, Iwona
author_facet Steckiewicz, Karol P
Cieciórski, Piotr
Barcińska, Ewelina
Jaśkiewicz, Maciej
Narajczyk, Magdalena
Bauer, Marta
Kamysz, Wojciech
Megiel, Elżbieta
Inkielewicz-Stepniak, Iwona
author_sort Steckiewicz, Karol P
collection PubMed
description PURPOSE: Periodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-CHL) or metronidazole (AgNPs-PEG-MET) to determine whether they can be used to treat PDs. MATERIALS AND METHODS: AgNPs were synthesized and characterized by transmission electron microscopy, UV-vis spectrometry, thermogravimetric analyses, and dynamic light scattering. We determined the safety and the antimicrobial and anti-inflammatory properties of synthesized AgNPs in an in vitro model of periodontitis. Antimicrobial properties were determined by measuring the minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) on reference strains of bacteria and fungi. Human gingival fibroblast (HGF-1), murine macrophage (RAW264.7) and human foetal osteoblast (hFOB1.19) cells were used in the study. Lipopolysaccharide (LPS) was used to induce inflammation. Cytokine levels were measured using an enzyme-linked immunosorbent assay; metalloproteinase expression was measured using Western blotting. RESULTS: The synthesized AgNPs were spherical and narrow-dispersed with an average diameter of 13.4 nm ± 3.0 nm in the case of AgNPs-CHL and 3.72 nm ± 0.72 nm in the case of AgNPs-PEG-MET. Both types of AgNPs were active against bacteria and fungi. AgNPs-CHL proved to be a more potent antimicrobial agent, although they were more cytotoxic than AgNPs-PEG-MET; however, both demonstrated beneficial properties in nontoxic concentrations. AgNPs-CHL and AgNPs-PEG-MET decreased the production of proinflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. Both agents also decreased the levels of metalloproteinases MMP3 and MMP8, which may indicate that they will inhibit tissue degradation. CONCLUSION: AgNPs-CHL and AgNPs-PEG-MET may be possible therapeutic options for PD, as they have antibacterial and anti-inflammatory properties. However, to fully understand the potential of AgNPs, our in vitro findings must be evaluated in an in vivo model.
format Online
Article
Text
id pubmed-8820264
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88202642022-02-08 Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis Steckiewicz, Karol P Cieciórski, Piotr Barcińska, Ewelina Jaśkiewicz, Maciej Narajczyk, Magdalena Bauer, Marta Kamysz, Wojciech Megiel, Elżbieta Inkielewicz-Stepniak, Iwona Int J Nanomedicine Original Research PURPOSE: Periodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-CHL) or metronidazole (AgNPs-PEG-MET) to determine whether they can be used to treat PDs. MATERIALS AND METHODS: AgNPs were synthesized and characterized by transmission electron microscopy, UV-vis spectrometry, thermogravimetric analyses, and dynamic light scattering. We determined the safety and the antimicrobial and anti-inflammatory properties of synthesized AgNPs in an in vitro model of periodontitis. Antimicrobial properties were determined by measuring the minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) on reference strains of bacteria and fungi. Human gingival fibroblast (HGF-1), murine macrophage (RAW264.7) and human foetal osteoblast (hFOB1.19) cells were used in the study. Lipopolysaccharide (LPS) was used to induce inflammation. Cytokine levels were measured using an enzyme-linked immunosorbent assay; metalloproteinase expression was measured using Western blotting. RESULTS: The synthesized AgNPs were spherical and narrow-dispersed with an average diameter of 13.4 nm ± 3.0 nm in the case of AgNPs-CHL and 3.72 nm ± 0.72 nm in the case of AgNPs-PEG-MET. Both types of AgNPs were active against bacteria and fungi. AgNPs-CHL proved to be a more potent antimicrobial agent, although they were more cytotoxic than AgNPs-PEG-MET; however, both demonstrated beneficial properties in nontoxic concentrations. AgNPs-CHL and AgNPs-PEG-MET decreased the production of proinflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. Both agents also decreased the levels of metalloproteinases MMP3 and MMP8, which may indicate that they will inhibit tissue degradation. CONCLUSION: AgNPs-CHL and AgNPs-PEG-MET may be possible therapeutic options for PD, as they have antibacterial and anti-inflammatory properties. However, to fully understand the potential of AgNPs, our in vitro findings must be evaluated in an in vivo model. Dove 2022-02-02 /pmc/articles/PMC8820264/ /pubmed/35140461 http://dx.doi.org/10.2147/IJN.S339046 Text en © 2022 Steckiewicz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Steckiewicz, Karol P
Cieciórski, Piotr
Barcińska, Ewelina
Jaśkiewicz, Maciej
Narajczyk, Magdalena
Bauer, Marta
Kamysz, Wojciech
Megiel, Elżbieta
Inkielewicz-Stepniak, Iwona
Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
title Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
title_full Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
title_fullStr Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
title_full_unstemmed Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
title_short Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis
title_sort silver nanoparticles as chlorhexidine and metronidazole drug delivery platforms: their potential use in treating periodontitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820264/
https://www.ncbi.nlm.nih.gov/pubmed/35140461
http://dx.doi.org/10.2147/IJN.S339046
work_keys_str_mv AT steckiewiczkarolp silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT cieciorskipiotr silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT barcinskaewelina silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT jaskiewiczmaciej silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT narajczykmagdalena silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT bauermarta silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT kamyszwojciech silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT megielelzbieta silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis
AT inkielewiczstepniakiwona silvernanoparticlesaschlorhexidineandmetronidazoledrugdeliveryplatformstheirpotentialuseintreatingperiodontitis